Search results
Katherine A. High is an American doctor-scientist who is an emeritus professor at the Perelman School of Medicine at the University of Pennsylvania. She was the co-founder, president, and chief scientific officer of Spark Therapeutics and currently serves as President of Therapeutics at AskBio.
Oct 27, 2016 · Our Faculty. Katherine A. High, M.D. Emeritus Professor of Pediatrics (Hematology) Attending Physician, The Children's Hospital of Philadelphia. Attending Physician, Hospital of the University of Pennsylvania. Attending Physician, Presbyterian Hospital Medical Center.
Oct 27, 2016 · Dr. High, a world renowned hematologist, studies the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Her pioneering bench-to-bedside studies of gene therapy for hemophilia have led to a focus on clinical translation of genetic therapies for hemophilia and other rare ...
Mar 15, 2017 · Katherine A. High is Emeritus Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. A renowned hematologist, her research group pioneered safe and effective clinical translation of genetic therapies for inherited disorders.
Katherine A. High, MD. Dr. High is co-founder, president, and chief scientific officer of Spark Therapeutics in Philadelphia. In this edition, Katherine A. High, MD, talks about her work in gene therapy, her love of reading, and the importance of "getting things done." What advice would you give to early-career hematologists and trainees?
May 6, 2021 · Dr. Katherine High trained in internal medicine, hematology, and molecular genetics. Her pioneering bench-to-bedside studies of gene therapy for hemophilia led to a series of basic and clinical investigations that characterized the human immune response to AAV gene delivery vectors.
Apr 4, 2023 · Physician-scientist and gene therapy pioneer, Dr. Katherine High, had a long career as an academic hematologist studying hemophilias and gene therapy vectors, before moving into industry. In both realms, High ( Figure 1) played a massive role in bringing forward the first FDA-approved gene therapy.
Katherine A. High is a researcher at Howard Hughes Medical Institute (HHMI), a non-profit medical research organization with headquarters in Maryland, and Director of the Center for Cellular and Molecular Therapeutics at the Childen's Hospital of Philadelphia.
Katherine High is recognized for her pioneering research and development of gene therapies for genetic disease. She is known for her studies in adeno-associated viral (AAV)-mediated gene therapy for hemophilia, including the development of AAV vectors that brought about long-term improvement in small and large animal models of hemophilia.
Dr. Kathy High, an accomplished hematologist with a longstanding interest in gene therapy for genetic disease, began her career studying the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders.
